Reasonable candidates include: Mild to moderate IBD as an adjunct (never as sole therapy, always with GI oversight) IBS with a documented inflammatory component Post-infectious gut dysfunction where both tissue damage and persistent low-grade inflammation are present Mixed presentations, heartburn plus intestinal sensitivity plus food reactivity, where the clinical picture suggests multiple mechanisms Where this falls apart is when people treat it as a silver bullet
Patients should be very cautious with online peptide sellers, especially products labeled research only, products without patient-specific labeling, products without a prescribing clinician, and products with unclear pharmacy information
Cagrilintide + Tirzepatide Clinical Evidence Context Direct stack evidence No published human trial has tested cagrilintide + tirzepatide together
Tablets support the bodys natural production pathways, while injections do not
This reduction in glutathione levels is associated with increased susceptibility to oxidative stress and age-related health issues
One person with IBS reported that ten days of oral BPC157 calmed the cramps Id battled for years. Another poster claims fewer colds since starting, hinting at possible BPC157 immune system support